» Articles » PMID: 16806437

Nucleotide Excision Repair Genotype and the Incidence of Endometrial Cancer: Effect of Other Risk Factors on the Association

Overview
Journal Gynecol Oncol
Date 2006 Jun 30
PMID 16806437
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Certain nucleotide excision repair (NER) genotypes appear to be associated with an altered risk of endometrial cancer. These associations could be modified by characteristics and exposures that themselves influence risk of disease.

Methods: We conducted a population-based case-control study in western Washington State to address the role of specific NER genotypes in conjunction with relevant exposures, such as postmenopausal hormone therapy, obesity, parity, oral contraceptive use, and cigarette smoking on risk of endometrial cancer. Case women (n=371), ages 50-69 years, were diagnosed with invasive endometrial cancer between 1994 and 1999. Control women (n=420), matched to cases on age and county of residence, were selected using random-digit dialing (ages 50-65) and random selection from HCFA data files (ages 66-69).

Results: Risk of endometrial cancer was not associated with ERCC1, ERCC2 (XPD), ERCC4 (XPF), or ERCC5 (XPG) genotype. A reduced risk of endometrial cancer was observed with presence of the XPA g23a variant allele, but only among women with a history of oral contraceptive use (OR 0.47, 95% CI 0.32-0.69). A decreased risk associated with carriage of at least one variant allele for both XPC A499V and XPC K939Q was restricted to women with BMI<30 kg/m2 (OR 0.45, 95% CI 0.25-0.82). The size of the association between these genotypes and risk of endometrial cancer did not differ by postmenopausal hormone use, parity, or smoking.

Conclusions: Our study provides limited evidence for interactions between NER genotypes and DNA damage-causing exposures in the etiology of endometrial cancer. Subsequent studies are needed to confirm the observed associations.

Citing Articles

DNA Repair Gene (XPD, XRCC4, and XRCC1) Polymorphisms in Patients with Endometrial Hyperplasia: A Pilot Study.

Ozturk E, Pehlivan S, Balat O, Ugur M, Ozcan H, Erkilic S Med Sci Monit Basic Res. 2018; 24:146-150.

PMID: 30275440 PMC: 6178876. DOI: 10.12659/MSMBR.911041.


rs17655 G>C polymorphism associated with cancer risk: evidence from 60 studies.

Zhao J, Chen S, Zhou H, Zhang T, Liu Y, He J Aging (Albany NY). 2018; 10(5):1073-1088.

PMID: 29779017 PMC: 5990387. DOI: 10.18632/aging.101448.


The R156R ERCC2 polymorphism as a risk factor of endometrial cancer.

Michalska M, Samulak D, Jablonski F, Romanowicz H, Smolarz B Tumour Biol. 2015; 37(2):2171-6.

PMID: 26349749 DOI: 10.1007/s13277-015-4040-8.


Association between the XPG Asp1104His and XPF Arg415Gln polymorphisms and risk of cancer: a meta-analysis.

He X, Liu L, Wei W, Liu Y, Su J, Wang S PLoS One. 2014; 9(5):e88490.

PMID: 24802942 PMC: 4011698. DOI: 10.1371/journal.pone.0088490.


Genetic association between ERCC5 rs17655 polymorphism and lung cancer risk: evidence based on a meta-analysis.

Liang Y, Deng J, Xiong Y, Wang S, Xiong W Tumour Biol. 2014; 35(6):5613-8.

PMID: 24596032 DOI: 10.1007/s13277-014-1742-2.